Day One Biopharmaceuticals (DAWN) News Today $7.59 0.00 (0.00%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$7.58 0.00 (-0.07%) As of 08/28/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Vanguard Group Inc. Has $47.13 Million Position in Day One Biopharmaceuticals, Inc. $DAWNAugust 28 at 3:12 AM | marketbeat.comDay One Biopharmaceuticals, Inc. $DAWN Shares Acquired by Stonepine Capital Management LLCAugust 26 at 7:38 AM | marketbeat.com371,380 Shares in Day One Biopharmaceuticals, Inc. $DAWN Acquired by Algert Global LLCAugust 23, 2025 | marketbeat.comLauren Merendino Sells 3,766 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) StockAugust 21, 2025 | marketbeat.comCharles York II Sells 4,106 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) StockAugust 21, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Insider Adam Dubow Sells 4,365 SharesAugust 21, 2025 | marketbeat.comInsider Selling: Day One Biopharmaceuticals (NASDAQ:DAWN) CEO Sells 16,058 Shares of StockAugust 21, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Insider Lauren Merendino Sells 3,766 SharesAugust 20, 2025 | insidertrades.comDay One Biopharmaceuticals initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comH.C. Wainwright Reiterates ‘Buy’ Rating on Day One Biopharmaceuticals, Inc. (DAWN)August 19, 2025 | insidermonkey.comDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 7% - Should You Buy?August 17, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for DAWN Q3 Earnings?August 9, 2025 | marketbeat.comWedbush Issues Optimistic Estimate for DAWN EarningsAugust 9, 2025 | marketbeat.comWhat is Wedbush's Estimate for DAWN FY2028 Earnings?August 8, 2025 | marketbeat.comDay One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade)August 7, 2025 | seekingalpha.comDay One Biopharmaceuticals (NASDAQ:DAWN) Sets New 12-Month Low on Analyst DowngradeAugust 7, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given New $25.00 Price Target at HC WainwrightAugust 7, 2025 | marketbeat.comNeedham & Company LLC Issues Pessimistic Forecast for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock PriceAugust 7, 2025 | marketbeat.comDay One price target lowered to $25 from $36 at H.C. WainwrightAugust 7, 2025 | msn.comDay One Biopharmaceuticals (NASDAQ:DAWN) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPSAugust 6, 2025 | marketbeat.comDay One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ...August 6, 2025 | finance.yahoo.comDay One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c)August 5, 2025 | msn.comDay One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comDay One Biopharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 5, 2025 | seekingalpha.comDay One Reports Second Quarter 2025 Financial Results and Corporate ProgressAugust 5, 2025 | globenewswire.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Buy" by AnalystsAugust 5, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by BIT Capital GmbHAugust 4, 2025 | marketbeat.comDay One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025July 22, 2025 | globenewswire.comDay One Biopharmaceuticals (DAWN) to Release Quarterly Earnings on TuesdayJuly 22, 2025 | marketbeat.comCenterBook Partners LP Lowers Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)July 19, 2025 | marketbeat.comDAY ONE BIOPHARMACEUTICALS Earnings Preview: Recent $DAWN Insider Trading, Hedge Fund Activity, and More - NasdaqJuly 8, 2025 | nasdaq.comWhen Will Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Breakeven?July 1, 2025 | finance.yahoo.comDay One Biopharmaceuticals Inc News (DAWN) - Investing.comJune 24, 2025 | investing.comTimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN)June 23, 2025 | msn.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Buy" by BrokeragesJune 16, 2025 | marketbeat.comBank of America Corp DE Has $260,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)June 15, 2025 | marketbeat.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | finance.yahoo.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | globenewswire.comH.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PTJune 5, 2025 | msn.comJonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA ApprovalJune 5, 2025 | msn.comDay One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301June 4, 2025 | seekingalpha.comDay One Biopharmaceuticals (NASDAQ:DAWN) Trading 9% Higher - Still a Buy?June 3, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Millennium Management LLCJune 2, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.9% - Should You Sell?May 31, 2025 | marketbeat.comTwo Sigma Investments LP Cuts Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)May 31, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from BrokeragesMay 24, 2025 | marketbeat.comNorthern Trust Corp Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)May 22, 2025 | marketbeat.comVestal Point Capital LP Sells 1,060,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)May 21, 2025 | marketbeat.comTema Etfs LLC Invests $1.09 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)May 20, 2025 | marketbeat.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 3,927 Shares of StockMay 20, 2025 | insidertrades.com Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DAWN Media Mentions By Week DAWN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼1.801.03▲Average Medical News Sentiment DAWN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼44▲DAWN Articles Average Week Get the Latest News and Ratings for DAWN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Day One Biopharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Immunovant News Today Recursion Pharmaceuticals News Today Catalyst Pharmaceuticals News Today Kiniksa Pharmaceuticals International News Today Organon & Co. News Today Alvotech News Today Centessa Pharmaceuticals News Today ImmunityBio News Today Tarsus Pharmaceuticals News Today Ocular Therapeutix News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access